Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre Phase II Trial of GVHD Prophylaxis Following Unrelated Donor Stem Cell Transplantation Comparing Thymoglobulin vs. Calcineurin Inhibitor or Sirolimus-based Post-transplant Cyclophosphamide

NCT04888741 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT04888741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04888741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre Phase II Trial of GVHD Prophylaxis Following Unrelated Donor Stem Cell Transplantation Comparing Thymoglobulin vs. Calcineurin Inhibitor or Sirolimus-based Post-transplant Cyclophosphamide
Lead sponsor
University of Birmingham
Phase
Phase 2
Overall status
Recruiting
Start date
February 22, 2021
Completion date
August 23, 2027
Enrollment
400 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, hodgkin lymphoma, multiple myeloma, myelodysplastic syndromes, myelofibrosis, non hodgkin lymphoma